This Article Full Text Full Text (PDF) Purchase Article View Shopping Cart Alert me when this article is cited Alert me if a correction is posted Services Email this article to a colleague Similar articles in this journal Alert me to new issues of the journal Download to citation manager Rights & Permissions Citing Articles Citing Articles via Google Scholar Google Scholar Articles by Bukowski, R. M. Search for Related Content PubMed Articles by Bukowski, R. M.

How I Treat Renal Cell Carcinoma

Because this article has no abstract, we have provided an extract of the first 100 words of the full text.

Renal cell carcinoma (RCC) accounts for 3% of malignant tumors and is the sixth leading cause of cancer death in the United States. An estimated 51,000 new renal tumors were diagnosed in 2006, with 13,000 deaths.¹ It is most common in the sixth decade of life, and a male to female predominance of 1.6 to 1.0 is present. Current therapeutic approaches for treatment of patients with metastatic RCC utilize knowledge of histology, molecular abnormalities, clinical prognostic factors, and the effects of available agents.

	Histologic Subsets

 
Epithelial RCC includes various histologic subtypes, each having unique morphologic and genetic characteristics. Clear-cell RCC is the . . . [Click for More]